LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

Home・Akciju saraksts・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Slēgts

3.75 7.14

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.56

Max

3.76

Galvenie mērījumi
By Trading Economics
Ienākumi	-136K -35M
EPS	-0.503
Darbinieki	106
EBITDA	-619K -38M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+86.67% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-34M 261M
Iepriekšējā atvēršanas cena	-3.39
Iepriekšējā slēgšanas cena	3.75

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 12. jūn. 23:56 UTC

Mondelez International shares declined in after-market trading, continuing a trend of three consecutive lower closes amid rising US Treasury yields and mixed economic signals.

2026. g. 12. jūn. 23:56 UTC

ETF Constituents

Macro News

The U.S. government acquired a 10% stake in USA Rare Earth, boosting investor sentiment for gold-mining firms and contributing to GDX's after-market gains.

2026. g. 12. jūn. 23:51 UTC

Asia equity markets rise on U.S.-Iran peace deal optimism, while U.S. producer prices signal persistent inflation ahead of Fed's interest rate decision.

2026. g. 12. jūn. 23:51 UTC

Global equity markets rise on U.S.-Iran peace deal optimism, while U.S. consumer sentiment improves amid easing inflation concerns.

2026. g. 12. jūn. 23:51 UTC

European equity markets rise on optimism for U.S.-Iran peace deal, despite mixed economic data from the UK and easing inflation in Germany.

2026. g. 12. jūn. 23:51 UTC

US equity markets show mixed performance amid geopolitical developments and rising inflation concerns, with key economic indicators and Fed decisions on the horizon.

2026. g. 12. jūn. 23:51 UTC

U.S. Industrial Production MoM data set for June 15, 2026, forecasts a cautious optimism with a predicted increase of 0.2% following April's strong performance.

2026. g. 12. jūn. 23:51 UTC

United Airlines Holdings Inc. shares declined in after-market trading, despite initial gains, amid rising U.S. Treasury yields and mixed economic signals.

2026. g. 12. jūn. 23:46 UTC

Take-Two Interactive shares are higher in after-market trading, reflecting a modest gain since Friday's close, though still below the 20-day moving average.

2026. g. 12. jūn. 23:46 UTC

JD.Com Inc. shares are higher in after-market trading, despite no specific news. The stock is near the lower end of its one-month range.

2026. g. 12. jūn. 23:46 UTC

ETF Constituents

iShares MSCI South Korea ETF rises in after-hours trading, supported by top holding SKM. Global equity markets remain mixed amid geopolitical developments.

2026. g. 12. jūn. 23:41 UTC

Check Point Software Technologies shares are higher in after-market hours, with trading notably strong despite no specific news driving the movement.

2026. g. 12. jūn. 23:41 UTC

U.S. Retail Sales Expected to Rise 0.5% in May Amid Cautious Consumer Sentiment and Geopolitical Tensions

2026. g. 12. jūn. 23:41 UTC

Cautious Optimism Surrounds Upcoming Canadian Housing Price Index Release Amidst Government Initiatives to Stabilize Market

2026. g. 12. jūn. 23:41 UTC

U.S. Retail Sales Ex Autos Expected to Rise 0.5% in May Amid Economic Uncertainties and Inflation Pressures

2026. g. 12. jūn. 23:41 UTC

Biomarin Pharmaceutical shares traded lower in after-market hours, reflecting broader market dynamics amid rising bond yields and mixed equity performance.

2026. g. 12. jūn. 23:41 UTC

Fox Corp. shares are higher in after-market trading, reflecting a strong upward trajectory since Friday's close amid notable volatility.

2026. g. 12. jūn. 23:41 UTC

Baidu Inc. shares advanced in after-market trading, reaching a session high. The stock remains below its 20-day moving average amid rising bond yields.

2026. g. 12. jūn. 23:41 UTC

Correlated Moves

Bitcoin is trading lower on Friday, influenced by rising bond yields and a broader market decline in cryptocurrencies, including Ethereum.

2026. g. 12. jūn. 23:36 UTC

iShares Core U.S. Aggregate Bond ETF was roughly flat in after-market hours, maintaining stability near the upper end of its one-month trading range.

2026. g. 12. jūn. 23:36 UTC

Ross Stores Inc. shares declined in after-market trading, reflecting routine fluctuations. Broader market conditions were influenced by rising bond yields.

2026. g. 12. jūn. 23:36 UTC

The SPDR S&P Regional Banking ETF traded roughly flat in after-market hours, reflecting routine trading patterns amid mixed direction in broader U.S. stock indices.

2026. g. 12. jūn. 23:31 UTC

ETF Constituents

Macro News

Energy Select Sector SPDR Fund is lower in after-market hours, impacted by declines in Chevron and ExxonMobil, as broader market dynamics influence energy outlook.

2026. g. 12. jūn. 23:31 UTC

Market Awaits U.S. Building Permits Data Amid Mixed Sentiment and Economic Concerns Ahead of June 16 Release.

2026. g. 12. jūn. 23:31 UTC

Trip.com Group Ltd shares are higher in after-market trading, reaching a peak despite three consecutive lower daily finishes and being below its 20-day moving average.

2026. g. 12. jūn. 23:26 UTC

ETF Constituents

Macro News

The Industrial Select Sector SPDR Fund is trading higher in after-market hours, supported by positive industrial sector developments and gains among key holdings.

2026. g. 12. jūn. 23:26 UTC

ETF Constituents

The Materials Select Sector SPDR Fund is trading higher in after-market hours, supported by contributions from Freeport-McMoRan and Albemarle.

2026. g. 12. jūn. 23:22 UTC

Preliminary May 2026 Building Permits Data Set for Release Amid Cautious Optimism Following April's 5.8% Increase

2026. g. 12. jūn. 23:22 UTC

U.S. Export Prices Expected to Surge Amid Optimism from Geopolitical Developments and Recent Inflation Trends Ahead of June 16 Release

2026. g. 12. jūn. 23:22 UTC

Market Awaits May Housing Starts Data Amid Optimism for Real Estate Recovery and Government Initiatives on June 16, 2026.

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

86.67% augšup

Prognoze 12 mēnešiem

Vidējais 7 USD 86.67%

Augstākais 10 USD

Zemākais 4 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

7 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 7 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.